Skip to main content

Table 8 Longitudinal, terminal and histological measurements after in vivo pravastatin treatment

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

 

CKD ( n = 6)

CKD + pravastatin ( n = 5)

Focal glomerulosclerosis (%)

  

 Normal

32.9 ± 7.6

23.4 ± 13.1

 Partial

48.1 ± 10.6

62.7 ± 10.4

 Total

19.0 ± 6.7

14.0 ± 15.8

Tubulo-interstitial damage

  

 Fibrosis

0.78 ± 0.31

0.85 ± 0.14

 Inflammation

1.72 ± 0.54

1.66 ± 0.22

 Atrophy

1.09 ± 0.65

0.56 ± 0.09

  1. Data presented as mean ± standard deviation. CKD, chronic kidney disease.